Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases
Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases
复制标题
DOI：
10.1080/00952990701653875
复制
发表时间：
2007-01-01
影响因子：
2.7
通讯作者：
Altice, Frederick L.
中科院分区：
文献类型：
--
作者：
Bruce, Robert D.;Altice, Frederick L.
背景：丙型肝炎病毒（HCV）是美国最常见的慢性病毒性疾病。许多HCV病毒感染者是阿片类药物依赖者，需要阿片类药物替代治疗，如丁丙诺啡。先前的文献报道表明丁丙诺啡的肝毒性降低了丁丙诺啡对hcv感染患者安全性的最初热情。方法：作为正在进行的samhsa资助的扩大丁丙诺啡阿片替代疗法的一部分，所有寻求丁丙诺啡治疗的阿片类药物依赖患者都要进行实验室评估，包括转氨酶（AST/ALT）以及急性和慢性肝炎的实验室评估。结果：筛选进入丁丙诺啡治疗的121例患者中，有4例患者有急性HCV感染的证据。结论：尽管急性肝炎感染患者的转氨酶明显升高，但这些患者在丁丙诺啡治疗期间转氨酶有所改善，并能耐受丁丙诺啡治疗。
Background: Hepatitis C virus (HCV) is the most prevalent chronic viral illness in the United States. Many individuals with virus HCV are opioid dependent requiring treatment with opiate substitution treatment such as buprenorphine. Previous reports in the literature have suggested hepatotoxicity with buprenorphine tempering initial enthusiasm of the safety of buprenorphine in HCV-infected patients. Methods: As part of an ongoing SAMHSA-funded grant to expand opiate substitution therapy with buprenorphine, all opioid-dependent patients seeking treatment with buprenorphine undergo a laboratory evaluation including transaminases (AST/ALT) as well as laboratory evaluation for acute and chronic hepatitis. Results: Of the 121 patients screened for entry into buprenorphine treatment, 4 patients had evidence of acute HCV infection. Conclusions: Despite markedly elevated transaminases in the setting of acute hepatitisCinfection, these patients tolerated buprenorphine treatment with improvement in their transaminases during the course of buprenorphine treatment.